Plus therapeutics to present data from respect™-gbm trial at the american association of neurological surgeons 2021 annual scientific meeting

Austin, texas, aug. 13, 2021 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult-to-treat cancers, today announced it will present data on rhenium-186 nanoliposome (186rnl) from its phase 1 respect™ clinical trial in recurrent glioblastoma (gbm) at the american association of neurological surgeons 2021 annual scientific meeting (aans) being held virtually august 21-25, 2021.
PSTV Ratings Summary
PSTV Quant Ranking